DREAM-PRIDE: Drug Eluting Stenting vs Medical Treatment for Recurrent Stroke in ICAD

Randomised, open-label trial in intracranial atherosclerotic disease (ICAD) and stroke (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Any stroke or death within 30 days of enrollment or any revascularization procedure OR an ischemic stroke in the territory of the symptomatic intracranial artery between 31 day to 1 year and Severe or moderate bleeding (GUSTO score) at 12 months. Started Jul 2021; status: recruiting.